{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:19:08Z","timestamp":1792441148113,"version":"4.5.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/inf.0b013e3182a222a6","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T07:27:23Z","timestamp":1372404443000},"page":"1340-1344","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacokinetics and Pharmacodynamics of Oral Cephalexin in Children With Osteoarticular Infections"],"prefix":"10.1097","volume":"32","author":[{"given":"Julie","family":"Autmizguine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Th\u00e9or\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastya","family":"Kassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Laferri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Tapi\u00e9ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ovetchkine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210202","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1302\/0301-620X.83B1.0830099","article-title":"The changing epidemiology of acute and subacute haematogenous osteomyelitis in children.","volume":"83","author":"Blyth","year":"2001","journal-title":"J Bone Joint Surg Br"},{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archpedi.1975.02120480007004","article-title":"Osteomyelitis in infants and children. A review of 163 cases.","volume":"129","author":"Dich","year":"1975","journal-title":"Am J Dis Child"},{"key":"R4-16-20210202","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1148\/radiology.204.3.9280235","article-title":"Peripherally inserted central catheters in infants and children.","volume":"204","author":"Dubois","year":"1997","journal-title":"Radiology"},{"key":"R5-16-20210202","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01241398-200205000-00009","article-title":"Short-term intravenous antibiotic treatment of acute hematogenous bone and joint infection in children: a prospective randomized trial.","volume":"22","author":"Jaberi","year":"2002","journal-title":"J Pediatr Orthop"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2334-2-16","article-title":"Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis: a systematic review.","volume":"2","author":"Le Saux","year":"2002","journal-title":"BMC Infect Dis"},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1542\/peds.2008-0596","article-title":"Prolonged intravenous therapy versus early transition to oral antimicrobial therapy for acute osteomyelitis in children.","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"R8-16-20210202","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/INF.0b013e3181f55a89","article-title":"Osteomyelitis-Septic Arthritis Study Group. Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases.","volume":"29","author":"Peltola","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R9-16-20210202","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.13.3.405","article-title":"Treatment of osteomyelitis and septic arthritis with cefazolin.","volume":"13","author":"Fass","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1440-1754.2005.00538.x","article-title":"Acute osteomyelitis and septic arthritis in children.","volume":"41","author":"Goergens","year":"2005","journal-title":"J Paediatr Child Health"},{"key":"R11-16-20210202","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1476-5381.1969.tb08513.x","article-title":"Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic.","volume":"37","author":"Gower","year":"1969","journal-title":"Br J Pharmacol"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2005.07.026","article-title":"A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.","volume":"40","author":"Kang","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"R14-16-20210202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/AAC.11.2.331","article-title":"Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine.","volume":"11","author":"Pfeffer","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-16-20210202","first-page":"ii","article-title":"Pharmacokinetic modeling of data with below quantification limit.","volume":"4","author":"Dorababu","year":"2012","journal-title":"J Bioequiv Availab"},{"key":"R18-16-20210202","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/adc.48.2.147","article-title":"Absorption and excretion of cephalexin by the newborn infant.","volume":"48","author":"Boothman","year":"1973","journal-title":"Arch Dis Child"},{"issue":"suppl B","key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/10.suppl_B.27","article-title":"Comparative pharmacokinetics of cefadroxil, cefaclor, cephalexin and cephradine in infants and children.","volume":"10","author":"Ginsburg","year":"1982","journal-title":"J Antimicrob Chemother"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/000992287301200213","article-title":"Staphylococcal osteomyelitis in children. Success with cephaloridine-cephalexin therapy.","volume":"12","author":"Walker","year":"1973","journal-title":"Clin Pediatr (Phila)"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0022-3476(78)80029-8","article-title":"Bioavailability of cephalexin in children: relationship to drug formulations and meals.","volume":"92","author":"Tetzlaff","year":"1978","journal-title":"J Pediatr"},{"key":"R22-16-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/j.1552-4604.1976.tb02402.x","article-title":"Pharmacokinetics of cephalexin: an evaluation of one- and two-compartment model pharmacokinetics.","volume":"16","author":"Greene","year":"1976","journal-title":"J Clin Pharmacol"},{"key":"R23-16-20210202","first-page":"463","article-title":"Cephalexin: pharmacologic evaluation following oral and parenteral administration.","volume":"13","author":"Nicholas","year":"1973","journal-title":"J Clin Pharmacol"},{"key":"R24-16-20210202","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/infdis\/132.6.637","article-title":"Pharmacokinetics of gentamicin in children and adults.","volume":"132","author":"Siber","year":"1975","journal-title":"J Infect Dis"},{"key":"R25-16-20210202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-3476(78)80133-4","article-title":"Developmental patterns of renal functional maturation compared in the human neonate.","volume":"92","author":"Arant","year":"1978","journal-title":"J Pediatr"},{"key":"R26-16-20210202","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/0009-9236(95)90021-7","article-title":"Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.","volume":"58","author":"van den Anker","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R27-16-20210202","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AM.16.11.1684-1694.1968","article-title":"Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults.","volume":"16","author":"Braun","year":"1968","journal-title":"Appl Microbiol"},{"key":"R28-16-20210202","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00000441-196808000-00008","article-title":"Cephalexin: in vitro bacterial susceptibility, absorption in volunteers, and antibacterial activity of sera and urine.","volume":"256","author":"Perkins","year":"1968","journal-title":"Am J Med Sci"},{"key":"R29-16-20210202","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.01325-09","article-title":"Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.","volume":"54","author":"Nannini","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-16-20210202","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/AAC.12.5.591","article-title":"Comparison of in vitro antibacterial activity of three oral cephalosporins: cefaclor, cephalexin, and cephradine.","volume":"12","author":"Silver","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-16-20210202","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1128\/AM.17.3.457-461.1969","article-title":"In vitro antimicrobial activity and human pharmacology of cephalexin, a new orally absorbed cephalosporin C antibiotic.","volume":"17","author":"Thornhill","year":"1969","journal-title":"Appl Microbiol"},{"key":"R33-16-20210202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (TMIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R34-16-20210202","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/infdis\/158.4.831","article-title":"Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.","volume":"158","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"R35-16-20210202","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1128\/JB.56.1.75-81.1948","article-title":"The action of penicillin on staphylococcus: further observations on the effect of a short exposure.","volume":"56","author":"Parker","year":"1948","journal-title":"J Bacteriol"},{"key":"R36-16-20210202","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0025-7125(16)32589-5","article-title":"Cephalexin.","volume":"54","author":"Griffith","year":"1970","journal-title":"Med Clin North Am"},{"key":"R37-16-20210202","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3109\/03009747709095460","article-title":"Cephalexin levels in serum, synovial fluid and joint tissues after oral administration.","volume":"6","author":"Jalava","year":"1977","journal-title":"Scand J Rheumatol"},{"key":"R38-16-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-3476(78)80094-8","article-title":"Oral antibiotic therapy for skeletal infections of children. I. Antibiotic concentrations in suppurative synovial fluid.","volume":"92","author":"Nelson","year":"1978","journal-title":"J Pediatr"},{"key":"R39-16-20210202","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0306-3623(90)91007-E","article-title":"Cephalexin concentrations in human serum, gingiva, and mandibular bone following a single oral administration.","volume":"21","author":"Akimoto","year":"1990","journal-title":"Gen Pharmacol"},{"issue":"suppl 5","key":"R40-16-20210202","first-page":"47","article-title":"A review of the drug events reported by 12,917 patients treated with cephalexin.","volume":"59","author":"Burt","year":"1983","journal-title":"Postgrad Med J"},{"key":"R41-16-20210202","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.41.4.739","article-title":"Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group.","volume":"41","author":"Tack","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-16-20210202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1542\/peds.61.1.94","article-title":"Nafcillin-induced neutropenia in children.","volume":"61","author":"Greene","year":"1978","journal-title":"Pediatrics"},{"key":"R43-16-20210202","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/infdis\/152.1.90","article-title":"Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics.","volume":"152","author":"Neftel","year":"1985","journal-title":"J Infect Dis"},{"key":"R44-16-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.16.1.1","article-title":"Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.","volume":"16","author":"Lode","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-16-20210202","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/j.1552-4604.1975.tb05918.x","article-title":"Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function.","volume":"15","author":"Brogard","year":"1975","journal-title":"J Clin Pharmacol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e3182a222a6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T14:06:19Z","timestamp":1645884379000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201312000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3182a222a6","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}